Last September, a 52-year-old project manager named David in Scottsdale came in with a DEXA scan showing a visceral adipose tissue score in the 89th percentile for his age. He'd been eating well, lifting three days a week, sleeping seven hours. His BMI was 27. Not alarming. But the visceral number was. "My doctor showed me the cross-section image and I looked like one of those before pictures in a journal article," he told his prescriber. Three months into compounded tesamorelin at 2 mg nightly, his repeat DEXA showed a 14% reduction in VAT. Total body weight? Down four pounds. Barely noticeable on a scale. Completely different story on the scan.
That gap between what the scale says and what's happening inside the abdomen is exactly why tesamorelin exists, and why it attracts so much confusion.
Tesamorelin is a stabilized 44-amino-acid synthetic analog of growth-hormone-releasing hormone (GHRH). The FDA approved it under the brand name Egrifta for one narrow purpose: reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The same active ingredient is also compounded by licensed 503A pharmacies for off-label clinical use, typically at a fraction of the branded product's cost, for adults with elevated visceral adiposity outside the HIV indication. Compounded tesamorelin is not FDA-approved for general weight loss. Any provider framing it that way is overstating what the regulatory record supports.
This guide covers what tesamorelin actually does at the molecular level, the published trial data (most of it from the Egrifta clinical program), realistic dosing and timelines, the side effects that actually matter, lab monitoring you can't skip, how it compares to sermorelin, and what compounded access looks like.
The Molecule and Why It's Different From Sermorelin
Tesamorelin is the full 44-amino-acid sequence of native GHRH with one critical tweak: a trans-3-hexenoic acid group attached at the N-terminus. That modification sounds small. It isn't. It dramatically extends the peptide's stability in circulation by resisting the enzymatic chewing that breaks down native GHRH (and sermorelin) within minutes.
The result: a more potent, longer-acting GH-axis stimulant. It binds the same GHRH receptor on the anterior pituitary that sermorelin targets, triggering cAMP-mediated signaling and endogenous growth hormone release. But the GH pulse it produces is more sustained. That sustained release drives higher hepatic IGF-1 production downstream, and IGF-1 is the effector molecule that does much of the work on body composition.
Here's the thing about visceral fat specifically: it's hormonally more active than subcutaneous fat and significantly more responsive to GH-axis stimulation. This is why tesamorelin produces a preferential reduction in visceral over subcutaneous adipose tissue. It's not magic selectivity. It's differential receptor density and hormonal sensitivity in the tissue itself.
The body's somatostatin feedback loop still operates, so you don't get the flat, unphysiological GH elevation that exogenous growth hormone injections produce. But the elevation is meaningfully higher and more prolonged than what sermorelin achieves at equivalent doses.
The FDA Approval and What It Does (and Doesn't) Cover
Egrifta received FDA approval in 2010 based on two phase 3 trials (M-002 and M-005) conducted by Falutz et al. and published in the New England Journal of Medicine in 2007 and 2008. The approved indication is narrow: reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.
That means Egrifta is not FDA-approved for general weight loss, non-HIV visceral fat, body composition optimization in healthy adults, or anything adjacent to the "longevity" and "anti-aging" language that populates social media.
Compounded tesamorelin is the same active ingredient prepared by a 503A pharmacy for an individual patient on a prescriber's order. It is not FDA-approved for any indication. Prescribers may write for it off-label based on published evidence and clinical judgment, but the regulatory status is "compounded prescription," full stop.
The pricing gap is enormous. Branded Egrifta runs $4,000 to $6,000 per month cash price. Compounded tesamorelin through FormBlends runs roughly $200 to $300 monthly at the standard 2 mg daily dose. Same active ingredient, vastly different regulatory wrapper. That difference should be communicated clearly to every patient.
Who It's Actually For (and Who It Isn't)
In clinical practice, compounded tesamorelin is most commonly prescribed for adults with:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Elevated visceral adiposity confirmed by waist circumference, DEXA VAT measurement, or CT
- A stable, reasonably well-controlled metabolic profile
- Body composition concerns that haven't budged with sustained dietary changes, resistance training, and sleep optimization
- Interest in GH-axis support that's more potent than sermorelin or sermorelin-based stacks
Where this falls apart is when patients want it as a weight loss tool. Tesamorelin is not a substitute for semaglutide or tirzepatide if the primary goal is total body weight reduction. Patients carrying mostly subcutaneous fat, or who simply want to weigh less, are poorly matched. GLP-1 receptor agonists produce 15 to 25 percent total weight loss through appetite suppression and altered glucose metabolism. Tesamorelin produces modest weight changes on a scale but targeted visceral fat loss, which is a different clinical outcome entirely.
Some prescribers combine them in selected patients. That's a reasonable conversation. But tesamorelin alone, pitched as a weight loss peptide, is a misapplication.
Dosing: What the Protocols Actually Look Like
Standard protocol. 2 mg subcutaneous, once daily, at bedtime.
Conservative start. 1 mg subcutaneous once daily for the first 2 to 4 weeks, then escalate to 2 mg if tolerated. This approach is common for patients who are peptide-naive or have any baseline metabolic concerns.
Injection site. Subcutaneous abdominal fat is preferred. Thigh and upper outer arm work too. Rotate sites to avoid localized reactions.
Why bedtime? Bedtime dosing aligns the induced GH elevation with the natural nocturnal GH pulse. Some prescribers use morning dosing, but bedtime is the standard for a reason.
Cycling. Tesamorelin is not cycled in the on-off pattern used for some other GH-axis peptides. Continuous daily dosing for 12 to 26 weeks is typical, then reassessment. The Egrifta studies showed clearly that visceral fat returns toward baseline after discontinuation, so sustained therapy is required to maintain the effect. Think of it less like a course of antibiotics and more like blood pressure medication: the intervention manages the condition rather than curing it.
Lab monitoring schedule. Baseline and periodic IGF-1 (target: upper half of age-adjusted reference range, not above the upper limit), fasting metabolic panel including glucose and lipid profile, and HbA1c. Repeat labs at 8 to 12 weeks and again at 6 months. Patients with any diabetes risk factors need tighter monitoring windows. Your specific protocol is determined by your prescriber.
The Side Effects That Actually Matter
The clinical trial data from the Egrifta program gives us a clear picture.
Common (reported in 5% or more of trial patients):
- Injection-site reactions (redness, itching, pain, bruising)
- Joint or extremity pain
- Peripheral edema
- Myalgia
- Headache
- Paresthesias (tingling, numbness)
Less common but clinically important:
- Hyperglycemia or worsening glucose tolerance
- IGF-1 elevation above reference range (requires dose reduction)
- Carpal tunnel syndrome
- Hypersensitivity reactions
Rare, contact your prescriber immediately:
- Severe allergic reaction
- New or worsening insulin resistance
- Persistent edema that doesn't resolve with dose adjustment
The boring truth is that most patients tolerate tesamorelin fine, with injection-site annoyance being the main complaint. But the one side effect that genuinely matters is the glucose signal.
GH-axis activation can worsen insulin sensitivity. The Egrifta trial population already had baseline metabolic abnormalities (HIV-lipodystrophy is metabolically messy), and even in that context, the published data showed modest worsening of fasting glucose in a subset of patients. For anyone with pre-diabetes, type 2 diabetes, or a strong family history, this isn't a footnote. It's the primary risk to monitor. Baseline HbA1c and fasting glucose are non-negotiable before starting, and repeat testing at 8 to 12 weeks catches problems early.
Realistic Results Timeline
This is where expectations need calibrating. The Falutz et al. trials and subsequent post-market data give us the numbers.
Weeks 1 to 4. Mostly subjective. Many patients report deeper sleep, occasionally mild headache or injection-site irritation as things settle. Body composition changes are not yet visible or measurable.
Weeks 6 to 12. Initial measurable visceral fat reduction begins. The 12-week mark is when most prescribers pull interim labs (IGF-1, metabolic panel) and remeasure waist circumference or, ideally, repeat DEXA.
Weeks 12 to 26. This is the window where the Egrifta data showed the largest measurable changes. Falutz 2007 demonstrated approximately 15 to 20 percent reduction in visceral adipose tissue at 26 weeks in the HIV-lipodystrophy population.
Beyond 26 weeks. Continued use maintains the effect. Stop, and VAT drifts back toward baseline. There is no established "completion" endpoint for tesamorelin therapy; it continues as long as the benefit-to-risk ratio holds up.
Non-responders. A meaningful percentage of patients don't show measurable visceral fat reduction. It happens. Common next steps include dose adjustment, switching to or adding alternative GH-axis combinations (CJC-1295 + ipamorelin), or simply stopping if 26 weeks of therapy has produced nothing documentable on imaging.
Read the full tesamorelin results timeline.
Tesamorelin vs. Sermorelin: The Honest Comparison
These two get confused constantly because they're both GHRH analogs. The differences are real and clinically relevant.
Sermorelin is GHRH(1-29), a shorter fragment. Short half-life. Preserves the natural pulsatile GH release pattern beautifully. Less potent. Milder side-effect profile. Lower cost. It's the better fit for general GH-axis support: sleep improvement, recovery, modest body composition goals in patients who aren't dealing with significant visceral adiposity.
Tesamorelin is the stabilized full-length analog with the N-terminal modification. Longer half-life, more sustained GH elevation, more potent. It has published randomized controlled trial data on visceral fat (sermorelin does not). Stronger IGF-1 elevation. Higher cost. It's the tool you reach for when visceral fat reduction is the primary clinical target and sermorelin hasn't gotten the job done, or when the visceral burden is significant enough to justify the stronger intervention from the start.
My genuinely held opinion: sermorelin is the better default first-line GH-axis peptide for most patients. Tesamorelin should be reserved for patients with documented, measurable visceral adiposity as the driving concern. Starting everyone on the more potent option because it sounds more impressive is not good prescribing.
Patients are not typically on both simultaneously. Stacking two GHRH analogs is mechanistically redundant.
Read the full tesamorelin vs sermorelin comparison.
Cost and Access Through FormBlends
Branded Egrifta cash price in the U.S.: approximately $4,000 to $6,000 per month at the standard 2 mg daily dose. Insurance coverage exists for the FDA-approved HIV-lipodystrophy indication but is inconsistent and almost always requires prior authorization with documented HIV diagnosis and lipodystrophy.
Compounded tesamorelin cash price through FormBlends:
- 5 mg vial (roughly 2.5 days at 2 mg, 5 days at 1 mg): $30 to $50
- 10 mg vial (roughly 5 days at 2 mg, 10 days at 1 mg): $60 to $90
- Monthly supply at 2 mg daily (typically dispensed as 60 mg total): $200 to $300
- Monthly supply at 1 mg daily: $120 to $180
Insurance does not typically cover compounded tesamorelin. HSA and FSA card payment is generally accepted.
The price difference is striking, but it reflects a real distinction: FDA-approved branded specialty pharmaceutical versus pharmacy-compounded prescription. The active ingredient is identical. The regulatory wrapper is not.
Lab Monitoring: The Part You Can't Skip
Tesamorelin has the most clearly defined lab monitoring requirement of any peptide in the FormBlends catalog. This isn't optional. Patients who can't or won't comply with the monitoring schedule are generally not appropriate candidates.
Baseline (before starting):
- IGF-1
- Fasting metabolic panel (glucose, lipids, liver enzymes, kidney function)
- HbA1c
- Consider fasting insulin if baseline metabolic risk is present
- Body composition baseline: waist circumference at minimum, DEXA VAT if available
8 to 12 weeks:
- Repeat IGF-1 (dose adjustment if above reference range)
- Repeat fasting glucose and lipid panel
- Body composition reassessment
6 months and ongoing:
- IGF-1
- Comprehensive metabolic panel
- HbA1c
- Body composition
The reason this monitoring exists is that tesamorelin's efficacy is verifiable (it raises IGF-1, it reduces visceral fat on imaging) and its primary safety concern (glucose metabolism) is detectable early with standard labs. Skipping monitoring isn't just careless; it removes the feedback loop that keeps dosing in the appropriate window.
Frequently Asked Questions
Is tesamorelin the same as Egrifta? The active ingredient is identical. Egrifta is the FDA-approved branded product. Compounded tesamorelin is the same molecule prepared by a licensed 503A pharmacy for an individual patient based on a prescriber's order. Different regulatory status, same chemistry.
Is tesamorelin a weight loss drug? No. It is researched and FDA-approved for visceral fat reduction in a specific clinical population. Effects on total body weight are modest. The peptide preferentially targets intra-abdominal fat.
Will tesamorelin work for subcutaneous fat? The published data shows a preferential effect on visceral over subcutaneous fat. Some subcutaneous reduction occurs, but the magnitude is smaller.
How does tesamorelin compare to GLP-1 medications like semaglutide? Completely different mechanism, different clinical target. Semaglutide and tirzepatide produce substantial total weight loss (15 to 25 percent) primarily through appetite suppression and altered glucose metabolism. Tesamorelin produces modest scale changes but targeted visceral fat reduction through GH-axis activation. For general overweight or obesity, GLP-1s are more powerful. For disproportionate visceral adiposity, tesamorelin has a more specific mechanism. Some prescribers combine them in selected patients.
How long until I see visceral fat changes? Measurable change at 12 weeks for most responders. Largest effects in the 16 to 26 week window.
Do I have to inject? Yes. Tesamorelin is administered by subcutaneous injection. It is not orally bioavailable and no oral preparation exists.
Will tesamorelin raise my blood sugar? It can. GH-axis activation affects glucose metabolism, and some patients experience modest fasting glucose elevation. This is exactly why baseline and periodic metabolic labs are required. Patients with pre-diabetes or diabetes need closer monitoring.
How to Get Tesamorelin Through FormBlends
- Complete the digital intake form, including detailed metabolic and body composition history
- Submit existing labs or have the prescriber order baseline panels
- Book the telehealth consult
- Discuss goals, baseline results, and protocol with the prescriber
- If clinically appropriate, the prescription is written
- The compounded preparation ships from a licensed 503A/503B compounding pharmacy
- Follow-up at 4 weeks (early tolerance check) and 8 to 12 weeks (full lab panel and body composition reassessment)
See tesamorelin compounded preparation pricing and order.
Back to peptide therapy overview.
---
Disclaimer: Compounded tesamorelin is not an FDA-approved drug. The FDA-approved branded product (Egrifta and Egrifta WR) is indicated for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Compounded tesamorelin is a prescription medication prepared by a licensed 503A compounding pharmacy for an individual patient based on a prescriber's clinical judgment, used off-label for related research interest. Research suggests potential benefits for visceral fat reduction; individual results vary. Tesamorelin is contraindicated in pregnancy, breastfeeding, active malignancy, and severe untreated hyperglycemia. Side effects can occur, including potential effects on glucose metabolism. Lab monitoring is required. Information on this page is for educational purposes and is not medical advice. Do not self-administer peptides obtained from unregulated sources.